These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 2867919

  • 1. Evidence for specific methylenedioxymethamphetamine (ecstasy) binding sites in the rat brain.
    Gehlert DR, Schmidt CJ, Wu L, Lovenberg W.
    Eur J Pharmacol; 1985 Dec 10; 119(1-2):135-6. PubMed ID: 2867919
    [No Abstract] [Full Text] [Related]

  • 2. [3H]3,4-methylenedioxymethamphetamine (MDMA) interactions with brain membranes and glass fiber filter paper.
    Wang SS, Ricaurte GA, Peroutka SJ.
    Eur J Pharmacol; 1987 Jun 26; 138(3):439-43. PubMed ID: 2887443
    [Abstract] [Full Text] [Related]

  • 3. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.
    Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB.
    J Pharmacol Exp Ther; 1987 Sep 26; 242(3):911-6. PubMed ID: 2443644
    [Abstract] [Full Text] [Related]

  • 4. 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors.
    Lyon RA, Glennon RA, Titeler M.
    Psychopharmacology (Berl); 1986 Sep 26; 88(4):525-6. PubMed ID: 2871581
    [Abstract] [Full Text] [Related]

  • 5. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents.
    Hekmatpanah CR, Peroutka SJ.
    Eur J Pharmacol; 1990 Feb 20; 177(1-2):95-8. PubMed ID: 1971219
    [Abstract] [Full Text] [Related]

  • 6. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
    McKenna DJ, Peroutka SJ.
    J Neurochem; 1990 Jan 20; 54(1):14-22. PubMed ID: 1967141
    [No Abstract] [Full Text] [Related]

  • 7. Intrasynaptosomal sequestration of [3H]amphetamine and [3H]methylenedioxyamphetamine: characterization suggests the presence of a factor responsible for maintaining sequestration.
    Zaczek R, Culp S, De Souza EB.
    J Neurochem; 1990 Jan 20; 54(1):195-204. PubMed ID: 1967142
    [Abstract] [Full Text] [Related]

  • 8. Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA.
    Gollamudi R, Ali SF, Lipe G, Newport G, Webb P, Lopez M, Leakey JE, Kolta M, Slikker W.
    Neurotoxicology; 1989 Jan 20; 10(3):455-66. PubMed ID: 2576302
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain.
    Schmidt CJ, Levin JA, Lovenberg W.
    Biochem Pharmacol; 1987 Mar 01; 36(5):747-55. PubMed ID: 2881549
    [Abstract] [Full Text] [Related]

  • 10. Ion trap tandem mass spectrometric evidence for the metabolism of 3,4-(methylenedioxy)methamphetamine to the potent neurotoxins 2,4,5-trihydroxymethamphetamine and 2,4,5-trihydroxyamphetamine.
    Lim HK, Foltz RL.
    Chem Res Toxicol; 1991 Mar 01; 4(6):626-32. PubMed ID: 1687259
    [No Abstract] [Full Text] [Related]

  • 11. Spectral and inhibitory interactions of (+/-)-3,4-methylenedioxyamphetamine (MDA) and (+/-)-3,4-methylenedioxymethamphetamine (MDMA) with rat hepatic microsomes.
    Brady JF, Di Stefano EW, Cho AK.
    Life Sci; 1986 Oct 20; 39(16):1457-64. PubMed ID: 2877380
    [Abstract] [Full Text] [Related]

  • 12. Stereochemistry of the metabolism of MDMA to MDA.
    Fitzgerald RL, Blanke RV, Rosecrans JA, Glennon RA.
    Life Sci; 1989 Oct 20; 45(4):295-301. PubMed ID: 2569654
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors.
    Schmidt CJ, Taylor VL.
    Eur J Pharmacol; 1990 May 31; 181(1-2):133-6. PubMed ID: 1974853
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Orally administered MDMA causes a long-term depletion of serotonin in rat brain.
    Finnegan KT, Ricaurte GA, Ritchie LD, Irwin I, Peroutka SJ, Langston JW.
    Brain Res; 1988 Apr 26; 447(1):141-4. PubMed ID: 2898273
    [Abstract] [Full Text] [Related]

  • 17. Effect of 3,4-methylenedioxymethamphetamine on [3H]paroxetine binding in the frontal cortex and blood platelets of rats.
    Nash JF, Arora RC, Schreiber MA, Meltzer HY.
    Biochem Pharmacol; 1991 Jan 01; 41(1):79-84. PubMed ID: 1702633
    [Abstract] [Full Text] [Related]

  • 18. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct.
    Hiramatsu M, Kumagai Y, Unger SE, Cho AK.
    J Pharmacol Exp Ther; 1990 Aug 01; 254(2):521-7. PubMed ID: 1974641
    [Abstract] [Full Text] [Related]

  • 19. Paroxetine as an in vivo indicator of 3,4-methylenedioxymethamphetamine neurotoxicity: a presynaptic serotonergic positron emission tomography ligand?
    Scheffel U, Ricaurte GA.
    Brain Res; 1990 Sep 10; 527(1):89-95. PubMed ID: 1980843
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.